In Vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study)

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2992-2994

  Walkty, A ^a   DeCorby, M ^b   Lagace Wiens P R S ^b   Karlowsky, J A ^a,b   Hoban, D J ^a,b   Zhanel, G G ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AVIBACTAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; DORIPENEM; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; BROTH DILUTION; CANADA; CLINICAL EVALUATION; EMERGENCY WARD; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY SYSTEM; SURGICAL WARD; URINE CULTURE; WOUND;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; CEFTAZIDIME; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 79956326529     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01696-10     Document Type: Article

References (19)

1. Aloush, V., S. Navon-Venezia, Y. Seigman-Igra, S. Cabili, and Y. Carmeli. 2006. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 50:43-48.
2. Biedenbach, D. J., G. J. Moet, and R. N. Jones. 2004. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY antimicrobial surveillance program (1997-2002). Diagn. Microbiol. Infect. Dis. 50:59-69.
3. Bonnefoy, A., et al. 2004. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J. Antimicrob. Chemother. 54:410-417.
4. Boucher, H. W., et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
5. CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 7th ed. CLSI M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
6. CLSI. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Gaynes, R., J. R. Edwards, and the National Nosocomial Infections Surveillance System. 2005. Overview of nosocomial infections caused by Gramnegative bacilli. Clin. Infect. Dis. 41:848-854.
8. Hoban, D. J., D. J. Biedenbach, A. H. Mutnick, and R. N. Jones. 2003. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY antimicrobial surveillance study (2000). Diagn. Microbiol. Infect. Dis. 45:279-285.
9. Lister, P. D., D. J. Wolter, and N. D. Hanson. 2009. Antibacterial- resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22:582-610.
10. Lodise, T. P., Jr., et al. 2007. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob. Agents Chemother. 51:3510-3515.
11. Mathai, D., R. N. Jones, M. A. Pfaller, and the SENTRY Participant Group North America. 2001. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY antimicrobial surveillance program (North America). Diagn. Microbiol. Infect. Dis. 40:129-136.
12. Mushtaq, S., M. Warner, and D. M. Livermore. 2010. In vitro activity of ceftazidime + NXL104 against Pseudomonas aeruginosa and other nonfermenters. J. Antimicrob. Chemother. 65:2376-2381.
13. Mushtaq, S., M. Warner, G. Williams, I. Critchley, and D. M. Livermore. 2010. Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 65:1428-1432.
14. Obritsch, M. D., D. N. Fish, R. MacLaren, and R. Jung. 2004. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother. 48:4606-4610. (Pubitemid 39577660)
15. Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2007. Doribax product monograph. Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ.
16. Sahm, D., et al. 2009. Activity of ceftazidime/NXL104 and select comparators against geographically diverse clinical isolates of Pseudomonas aeruginosa, abstr. E-194. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.
17. Shahid, M., et al. 2009. Beta-lactams and beta-lactamase-inhibitors in current or potential clinical practice: a comprehensive update. Crit. Rev. Microbiol. 35:81-108.
18. Stachyra, T., et al. 2010. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-β-lactam β-lactamase inhibitor. Antimicrob. Agents Chemother. 54:5132-5138.
19. Tam, V. H., et al. 2010. Impact of multidrug resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob. Agents Chemother. 54: 3717-3722.